Outcomes of Selective Laser Trabeculoplasty as Initial Treatment for Glaucoma
Overview
This study evaluates the efficacy of Selective Laser Trabeculoplasty (SLT) as a primary treatment for open-angle glaucoma in a Nigerian cohort. Results indicate significant intraocular pressure reduction, supporting SLT's role as a viable first-line therapy in this population.
Background
Glaucoma is a leading cause of irreversible blindness, necessitating effective management strategies to lower intraocular pressure (IOP). Traditional treatments often face challenges such as poor adherence and side effects, particularly in developing regions. SLT has emerged as a promising alternative, offering effective IOP reduction with fewer complications.
Data Highlights
Parameter
Value
Sample Size
93 eyes from 50 patients
Follow-up Duration
Minimum 3 months
IOP Reduction Range
30-40% at 12 months
Key Findings
SLT effectively reduced IOP in treatment-naïve patients with open-angle glaucoma.
Mean IOP reductions at 12 months ranged from 30% to 40%.
Over 80% of patients maintained a reduction of 20% in IOP one year post-treatment.
SLT is gaining acceptance as a primary treatment option despite barriers such as cost and equipment availability.
This study is the first to assess SLT in treatment-naïve eyes in southeastern Nigeria.
Clinical Implications
The findings support the use of SLT as a first-line treatment for open-angle glaucoma, particularly in regions with limited access to medications. Clinicians should consider SLT for patients who may struggle with adherence to topical therapies.
Conclusion
SLT demonstrates significant efficacy in lowering IOP in a Nigerian cohort, reinforcing its potential as a primary treatment for glaucoma. Further studies are warranted to explore its long-term outcomes in diverse populations.
